MedCap Corp Acquires Exclusive Rights To Rapid Test That Detects Sexually Transmitted Diseases

TORONTO, Nov. 30 /PRNewswire-FirstCall/ -- MedCap Corp (Pinksheets: MPCPF) is pleased to announce that it has acquired the exclusive right to market and distribute a rapid test kit for the detection of syphilis. Syphilis is a sexually transmitted disease (STD) that is becoming more and more prevalent in many countries in the world. With early detection, syphilis is easily cured through a single dose of penicillin taken as an intra muscular injection. World Health Organization (WHO) estimates that there are 340 million new cases of syphilis and other STD's each year. The largest number of new infections has occurred in South and Southeast Asia, followed by sub-Saharan Africa, Latin America and the Caribbean.

Individuals with syphilis have a 3 to 5 time increase in the risk of transmitting and acquiring an HIV infection when syphilis is present.

The Company feels that there is a virtually untouched market for a rapid diagnostic test kit related to the detection of syphilis that is easy to use, a reasonable price and very accurate (greater than 99%). The acquisition of the exclusive rights to this syphilis test kit will result in substantial cashflow for the Company.

MedCap Corp trades in the United States on the Pinksheets under the symbol "MPCPF". For further information, please contact Cazgeld Capital Corporation at (416) 363 0070 or http://www.medccap.com/ .

NOTE: This release may contain forward-looking statements that involve uncertainties and risks. Actual results may differ materially from any results predicted. MedCap undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events of circumstances after the date hereof.

CONTACT: Cazgeld Capital Corporation, +1-416-363-0070, for MedCap Corp

Web site: http://www.medccap.com/